Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...gnosis
...Risk in Patients With Nonvalvular AF Not T...
...igure 1. Patterns of Atrial Fibrillation
Treatment
...eatment...
...arfarin (A)300167...
...atran (B)30016...
...xaban (B)300167...
...xaban (B)30016...
...and efficacy of combining dabigatran, ri...
... Clopidogrel & Warfarin...
...se warfarin (target INR – 2.0-3.0) is recommen...
...t therapy with aspirin is recommended...
...igh-risk patients with AF deemed unsuitable...
...h ischemic stroke or TIA with paroxysmal (int...
...n alone is recommended. (A)300167...
...combination of clopidogrel plus aspirin carrie...
...bigatran...
...ran is useful as an alternative to warf...
...150 mg twice daily is an efficacious alternativ...
...pharmacokinetic data, the use of dabigatran 75 m...
...cause there are no data to support the use of...
...ixaban
...an 5 mg twice daily is an efficaci...
Although its safety and efficacy have not...
...ban 5 mg twice daily is a relatively...
...its safety and efficacy have not been...
...ban should NOT be used if the...
Rivaroxa...
...atients with nonvalvular AF who are a...
...ents with renal impairment and nonvalvular AF who...
...an should NOT be used if the CrCI is...
...2. Agents Recommended for Stroke PreventionaHav...
...e 2. Prevention of Stroke in Nonvalvul...